Dr. Klein is a Faculty Fellow at the Center for Law, Science & Innovation at the Sandra Day O'Connor College of Law at Arizona State University. He is also Principal at Roger D. Klein, MD JD Consulting and Klein & Klein Co., L.P.A. He was formerly Chief Medical Officer at OmniSeq, an oncology focused genomic profiling company that was recently acquired by LabCorp. Previously, Roger was the Medical Director at the Molecular Oncology division at the Cleveland Clinic. He was also the Chair of the Professional Relations Committee at the Association for Molecular Pathology. Prior to joining the Cleveland Clinic, he served as Medical Director of Molecular Oncology at the BloodCenter of Wisconsin where he led the center’s Diagnostic Laboratories’ initiative focused on DNA- and RNA-based testing for evaluation of cancer patients.
Dr. Klein has been an advisor to the Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services (CMS), and the Centers for Disease Control and Prevention (CDC). He has participated in and assumed leadership roles in many professional society committees and corporate advisory boards and is a policy advisor to the Heartland Institute.
Dr. Klein is licensed to practice medicine in Ohio, Florida, and Wisconsin. Additionally, he is licensed to practice law in the District of Columbia and Ohio. Roger obtained his Molecular Genetic Pathology certification at Mayo Medical School following completion of his M.D. Yale University School of Medicine. He obtained his J.D. from Yale Law School.
*****
A person listed as a contributor has spoken or otherwise participated in Federalist Society events, publications, or multimedia presentations. A person's appearance on this list does not imply any other endorsement or relationship between the person and the Federalist Society. In most cases, the biographical information on a person's "contributor" page is provided directly by the person, and the Federalist Society does not edit or otherwise endorse that information. The Federalist Society takes no position on particular legal or public policy issues. All expressions of opinion by a contributor are those of the contributor.
Litigation Update: AHM v. FDA: Challenging the FDA on “Chemical Abortion Drugs"
A Regulatory Transparency Project Webinar
Deep Dive Episode 117 – How to Approach Data Collection and Breaches in the Age of COVID-19
Regulatory Transparency Project Teleforum
TeleforumRegulation or “Don’t Let a Good Crisis Go to Waste”
COVID-19 & the Law Conference
Webinar & Live StreamDeep Dive Episode 98 – Regulatory Reforms and the COVID Pandemic
Regulatory Transparency Project Teleforum
TeleforumUniversal Healthcare
Northern Illinois Student Chapter
Northern Illinois University College of Law1425 W. Lincoln Hwy
Dekalb, IL 60115
Explainer Episode 55 - 10 Years On: The Impact and Effects of AMP vs. Myriad
Regulatory Transparency Project's Fourth Branch Podcast
On June 13, 2013, the Supreme Court issued its unanimous decision in Association for Molecular...
Explainer Episode 53 - Biologics, Biosimilars, and the Two-fold U.S. Approval Framework’s Possible Impact on Prices
Regulatory Transparency Project's Fourth Branch Podcast
Biosimilars, a category of biologic (medicine derived from a living organism), require approval, at least...
Litigation Update: AHM v. FDA: Challenging the FDA on “Chemical Abortion Drugs"
A Regulatory Transparency Project Webinar
In November 2022, the Alliance Defending Freedom (ADF) filed a federal lawsuit in the U.S....
Litigation Update: AHM v. FDA: Challenging the FDA on “Chemical Abortion Drugs"
A Regulatory Transparency Project Webinar
In November 2022, the Alliance Defending Freedom (ADF) filed a federal lawsuit in the U.S....
Deep Dive Episode 117 – How to Approach Data Collection and Breaches in the Age of COVID-19
Regulatory Transparency Project Teleforum
In an effort to combat the spread of COVID-19 and contain its impact, nations across...